Platelet glycoprotein complex Ia/IIa antibodies cause neonatal alloimmune thrombocytopenia but do not inhibit megakaryopoiesis and platelet recovery after allogeneic cord blood stem cell transplantation

Cassens, U.; Garritsen, Henk; Kelsch, Reinhard; Werf, Nienke van der; Frosch, Michael; Witteler, Ralf; Ebell, Wolfram; Sibrowski, W.

doi:10.1038/sj.bmt.1703235

Cited by 4 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the presented patients was a 7-year-old boy with Wiskott-Aldrich syndrome. He was successfully transplanted with the directed cord blood of his sibling [20]. The collection of cord blood after birth is relatively simple and without any risk for the mother or the child.…”

Section: Discussionmentioning

confidence: 99%

Potential of Directed Cord Blood Donations for the Treatment of Patients with Hematologic Disorders

Brune

Garritsen

2007

Transfus Med Hemother

View full text Add to dashboard Cite

Directed cord blood donations are donations in which a family that has a child or other family member with a malignant or nonmalignant disease that is potentially treatable with stem cell transplantation, banks cord blood in subsequent pregnancies for future transplantation. With the present study we evaluate the effectiveness of directed cord blood donations. Patients and Methods: Within a 3-year period we analyzed directed cord blood collections in 27 families in which a family member had a malignant (primary hematological) disease. Results: The amount of collected cord blood was 75 ml median (20-168 ml). The amount of CD34+ cells per collection varied from 0.13 × 10⁶ to 30.9 × 10 ⁶ (median 5.1 × 10 ⁶). Screening for bacterial contamination was negative in all collections. HLA typing of the collected cord blood showed HLA identity to the patient in 8 (25%) of the 32 cord blood collections. In 2 cases (6.25%) 1 HLA mismatch was found and in 10 cases (31.25%) 2 HLA mismatches. The other 12 (37.5%) collected cord blood samples displayed at least 3 HLA mismatches. Assuming 2 HLA mismatches as a cut-off for acceptance would mean that 62.5% of the patients in the investigated group would have an HLA-compatible directed cord blood donation. Conclusions: Our investigation showed that directed cord blood banking is a potential option in families with a family member which has a disorder potentially treatable with stem cell transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential of Directed Cord Blood Donations for the Treatment of Patients with Hematologic Disorders

Brune

Garritsen

2007

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…The expression of glycoprotein Ia/IIa on different progenitor cell subsets has not been investigated in detail. A case report about a sibling cord blood SCT from a donor with an acquired glycoprotein Ia/IIa antibody (HPA-5b) after neonatal alloimmune thrombocytopenia did not demonstrate an inhibition of hematopoiesis and engraftment [105]. However, clinical data on the potential influence of non-ABO erythrocyte antibodies or platelet-specific antibodies on the hematopoiesis and engraftment after allogeneic SCT are still very rare.…”

Section: Non-abo Blood Group Differences and Antibodiesmentioning

confidence: 99%

Relevance of Blood Group Differences and Antibodies in Allogeneic Stem Cell Transplantation

Cassens¹,

Sibrowski²

2002

Transfus Med Hemother

View full text Add to dashboard Cite

Improved experimental and clinical experiences resulted in continuously increasing numbers of allogeneic stem cell transplantation (SCT) during the past years. Nevertheless, severe immunologic side effects remain major risk factors. It is well known that disparities in major histocompatibility complex (MHC) genes and antigens play a dominant role in the induction of cellular immune responses, clinically manifested as graft versus host diseases (GVHD) or graft failures. In contrast, blood group differences, e.g. ABO incompatibilities, are often not considered as significant risk factors although severe clinical complications have been described after blood group-discrepant allogeneic SCT. Major ABO-incompatible SCT may lead to delayed cell engraftment and pure red cell aplasia. In contrast, minor ABO blood group incompatibilities are caused by administration of donor antibodies or by donor plasma cells leading to a passenger lymphocyte syndrome. Furthermore, several therapeutic methods such as T-cell depletion of stem cell transplants or treatment with cyclosporine without methotrexate are known as risk factors to develop immune hemolysis. Finally, it was recently demonstrated that other red blood cell antibodies such as anti-Kell inhibit the clonogenicity of erythrocyte and megakaryocyte progenitor cells and may therefore influence the engraftment after allogeneic SCT. Therefore, it is desirable for specialists in transfusion medicine to know the relevance of blood group antibodies in allogeneic SCT in order to perform diagnostic and/or therapeutic procedures. This article reflects the main immunologic and clinical risk factors in allogeneic SCT caused by blood group differences and corresponding antibodies.

show abstract

Stammzellen aus Nabelschnurblut

Schlenke

Cassens

Sibrowski

2010

Transfusionsmedizin Und Immunhämatologie

View full text Add to dashboard Cite

Platelet glycoprotein complex Ia/IIa antibodies cause neonatal alloimmune thrombocytopenia but do not inhibit megakaryopoiesis and platelet recovery after allogeneic cord blood stem cell transplantation

Cited by 4 publications

References 23 publications

Potential of Directed Cord Blood Donations for the Treatment of Patients with Hematologic Disorders

Potential of Directed Cord Blood Donations for the Treatment of Patients with Hematologic Disorders

Relevance of Blood Group Differences and Antibodies in Allogeneic Stem Cell Transplantation

Stammzellen aus Nabelschnurblut

Contact Info

Product

Resources

About